for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Orgenesis Inc

ORGS.OQ

Latest Trade

4.32USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

3.80

 - 

9.25

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.32
Open
--
Volume
--
3M AVG Volume
0.45
Today's High
--
Today's Low
--
52 Week High
9.25
52 Week Low
3.80
Shares Out (MIL)
16.14
Market Cap (MIL)
69.73
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2019 Orgenesis Inc Earnings Release

Latest Developments

More

Orgenesis Reorganizes Its Israel And Korea Subsidiaries

Orgenesis Q2 Revenue Up 95% To $7.8 Million

Orgenesis Granted FDA Orphan Drug Designation For Autologous Insulin Producing Cells

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Orgenesis Inc

Orgenesis Inc. is a regenerative therapy company. The Company operates through two segments: Contract Development and Manufacturing Organization (CDMO) and Cellular Therapy Business (CTB). The CDMO activity is operated by the Company's subsidiary, MaSTherCell SA, which specializes in cell therapy development for advanced medicinal products. MaSTherCell is providing two types of services to its customers: process and assay development services and good manufacturing practice (GMP) contract manufacturing services. The CTB activity is based on its technology that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating (converting) them into pancreatic beta cell-like insulin producing cells for patients with Type I Diabetes. It intends to advance a product that combines cell-based therapy and regenerative medicine, Autologous Insulin Producing (AIP) cells, into clinical development.

Industry

Biotechnology & Drugs

Contact Info

20271 Goldenrod Ln

+1.480.6596404

https://www.orgenesis.com/

Executive Leadership

Vered Caplan

Chairman of the Board, Chief Executive Officer, President; Chief Executive Officer of Orgenesis Maryland Inc.

Neil T. Reithinger

Chief Financial Officer, Treasurer, Secretary

Sarah Ferber

Chief Scientific Officer

Yaron Adler

Director

David Sidransky

Director

Key Stats

Revenue (MM, USD)

2019(E)

0.0K
EPS (USD)

2019(E)

-0.810
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.57
Price To Book (MRQ)
4.32
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
71.99
LT Debt To Equity (MRQ)
64.18
Return on Investment (TTM)
-78.87
Return on Equity (TTM)
-38.64

Latest News

BRIEF-Orgenesis Reports Q1 Loss Per Share Of $0.52

* ORGENESIS REPORTS 42% INCREASE IN REVENUE FOR THE FIRST QUARTER OF FISCAL 2018

BRIEF-Orgenesis Files For Mixed Shelf Of Up To $100 Mln

* ORGENESIS INC FILES FOR MIXED SHELF OF UP TO $100 MILLION – SEC FILING Source text: (http://bit.ly/2HLAOaJ)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up